The Intercontinental Journal of Emergency Medicine aims to publish issues related to all fields of emergency medicine and all specialties involved in the management of emergencies in the hospital and prehospital environment of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Evaluation of the use and efficacy of prothrombin complex concentrates in patients presenting to the emergency department with warfarin
Aims: Warfarin administration has been a standard treatment for preventing thromboembolism in patients with atrial fibrillation prosthetic heart valves for many years. It is one of the leading drugs implicated in emergency room visits for adverse drug reactions. Because of a narrow therapeutic window, as many as 3% to 7% of patients taking warfarin are at risk of significant, life-threatening bleeding, and it is generally considered that this requires rapid and complete warfarin reversal. Although there are treatments such as vitamin K and fresh frozen plasma to reverse the effects of warfarin, the most effective method involves using prothrombin complex concentrates (PCC). This study aims to evaluate the use and efficacy of PCC in patients with warfarin-induced bleeding in the emergency department.
Methods: The patients receiving PCC for warfarin reversal in the emergency department between January 1, 2019 – April 1, 2021, were identified from the hospital's electronic database. Demographic data, reasons for warfarin use, PCC indications, INR values before and after PCC, and mortality of the patients were evaluated. The four-factor PCC dose was determined according to the patient's body weight, admission INR level, and target INR level. The study was conducted with 73 patients.
Results: The mean age of the patients was 69.3 ± 15.5 years. The female/male ratio was 1/1.5. The most common PCC indications were gastrointestinal bleeding (32.9%), urogenital bleeding (23.3%), epistaxis (12.3%), and urgent surgical need (12.3%), respectively. The median international normalized ratio (INR) before and after treatment with PCC was 9.2 (min-max 2.1-11.8) and 1.8 (min-max 1.0-4.6). The mean dose of PCC was 1500 IU (min-max 750-3250 IU). In addition to PCC, all patients received vitamin K; 17.8% received erythrocyte suspension, and 10.9% received fresh frozen plasma. There were no PCC-related complications in the emergency department. While 38.4% of the patients consulted the inpatient services after the emergency department, 5.5% were referred to an external center, and 56.2% were discharged from the emergency department after successful treatment. 26% of the patients were followed in the intensive care unit. No patient died in the emergency department. However, in-hospital mortality was 5.5%.
Conclusion: Four-factor PCC is an effective and safe treatment for reversing warfarin-associated bleeding.

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, PalaretiG. Oral anticoagulant therapy. Chest. 2012;141(2):e44S-e88S. doi:10.1378/chest.11-2292
2. Hull RD, Garcia DA, Vazquez SR. Biology of warfarin and modulatorsof INR control. In: UptoDate. Leung LLK, ed. Available from: https://www.uptodate.com/contents/biology-of-warfarin-and-modulators-of-inr-control Accessed November 22, 2021.
3. Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS.An update of consensus guidelines for warfarin reversal. Med J Aust.2013;198(4):198-199. doi: 10.5694/mja12.10614
4. Guyatt GH, Akl EA, Crowther M, Gutterman DD, SchuünemannHJ. Executive summary: antithrombotic therapy and prevention ofthrombosis: American College of Chest Physicians evidence-basedclinical practice guidelines. Chest. 2012;141(2):7S-47S. doi: 10.1378/chest.1412S3
5. Franchini M, Lippi G. Prothrombin complex concentrates: an update.Blood Transfus. 2010;8(3):149-154. doi: 10.2450/2010.0149-09
6. Goldstein JN, Rosand J, Schwamm LH. Warfarin reversal inanticoagulant-associated intracerebral hemorrhage. Neurocrit Care.2008;9(2):277-283. doi: 10.1007/s12028-008-9049-z
7. Available from: http://cofact.centurion.com.tr/cetvel.php AccessedNovember 16, 2021.
8. Zareh M, Davis A, Henderson S. Reversal of warfarin-inducedhemorrhage in the emergency department. West J Emerg Med.2011;12(4):386-392. doi: 10.5811/westjem.2011.3.2051
9. Majeed A, Eelde A, Agren A, Schulman S, Holmström M.Thromboembolic safety and efficacy of prothrombin complexconcentrates in the emergency reversal of warfarin coagulopathy.Thromb Res. 2012;129(2):146-151. doi: 10.1016/j.thromres.2011.07.024
10. Appleby N, Groarke E, Crowley M, et al. Reversal of warfarinanticoagulation using prothrombin complex concentrate at 25 IUkg-1 : results of the RAPID study. Transfus Med. 2017;27(1):66-71. doi:10.1111/tme.12371
11. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H.Prothrombin complex concentrate (Beriplex P/N) for emergencyanticoagulation reversal: a prospective multinational clinicaltrial. J Thromb Haemost. 2008;6(4):622-631. doi: 10.1111/j.1538-7836.2008.02904.x
12. Soyuncu S, Aslan S, Mutlu H, Bektas F. Prothrombin complexconcentrates utility for warfarin-associated hemorrhage. Int J Clin ExpMed. 2015;8(2):2778-2783.
13. Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombincomplex concentrates vs fresh frozen plasma in gastrointestinalhemorrhage due to warfarin usage in the ED. Am J Emerg Med.2014;32(6):660-664. doi: 10.1016/j.ajem.2014.02.016
14. Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EFM,Rabinstein AA. Predictors of outcome in warfarin-related intracerebralhemorrhage. Arch Neurol. 2008;65(10):1320-1325. doi: 10.1001/archneur.65.10.1320
15. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinicalreview: prothrombin complex concentrates--evaluation of safety andthrombogenicity. Crit Care. 2011;15(1):201. doi: 10.1186/cc9311
16. Rech MA, Masic D, Hammond DA. Four-factor prothrombin complexconcentrate for reversal of factor Xa inhibitors versus warfarin inlife-threatening bleeding. West J Emerg Med. 2021;22(2):163-169. doi:10.5811/westjem.2020.11.47931
17. Brekelmans MPA, Ginkel K van, Daams JG, Hutten BA, MiddeldorpS, Coppens M. Benefits and harms of 4-factor prothrombin complexconcentrate for reversal of vitamin K antagonist associated bleeding:a systematic review and meta-analysis. J Thromb Thrombolysis.2017;44(1):118-129. doi: 10.1007/s11239-017-1506-0
18. Tran HA, Chunilal SD, Tran H. An update of consensus guidelines forwarfarin reversal. Med J Aust. 2014;200(2):82. doi: 10.5694/mja13.10685
19. Reilly RF, Jain N. Warfarin in nonvalvular atrial fibrillation-time for achange? Semin Dial. 2019;32(6):520-526. doi: 10.1111/sdi.12829
20. Toth P, van Veen JJ, Robinson K, et al. Real world usage of PCC to “rapidly” correct warfarin induced coagulopathy. Blood Transfus.2013;11(4):500-505. doi: 10.2450/2012.0113-12
Volume 2, Issue 2, 2024
Page : 25-30